Ramdev Launches Coronil for COVID, But Critical Questions Remain

Ramdev Launches Ayurvedic Drug Coronil, Claims it Can Treat COVID

4 min read
Ramdev Launches Coronil for COVID, But Critical Questions Remain

The Quint DAILY

For impactful stories you just can’t miss

By subscribing you agree to our Privacy Policy

As the medical world works tirelessly towards a vaccine for COVID-19, Patanjali has released a drug that claims a “100 percent recovery rate.”

On Tuesday, 23 June, Ramdev’s Patanjali launched the ayurvedic drug ‘Coronil and Swasari’ as the first ayurvedic treatment to the virus. They claimed that after clinical trials with patients infected with coronavirus, they can ascertain that this drug works to 100 percent treat the virus in 3-14 days, reported LiveMint.

So far no cure has been made and many ‘immunity-boosting’ medicines have been launched. However, Ramdev claims that,

The first case of coronavirus in India appeared on February 23, 2020. So far, no other science journal or research body has corroborated Patanjali’s claim of being the “first coronavirus cure.”

Neither the Ayush Ministry or the Indian Council of Medical Research (ICMR) have backed Patanjali’s claims. Government notifications have a strict ban on companies advertising medicinal products and cures without government approval. 

95 People Tested; Patanjali Claims the Drug Produces Lesser Risk of Cytokine Storm

At Patanjali’s launch event, they claimed to have tested 100 people infected with the virus for the drug. 4 withdrew consent, and 1 patient's details were lost in the trials and so they effectively tested the drug on 95 people.

This is a very small sample size to test against a drug, and we have no information as to the nature of the trials - were they randomised? If so, how many trials were conducted? How did the drug reach the clinical stage already? Ramdev added that this was the “first Ayurvedic clinically-controlled trial.”

They did provide some more insight into how patients were selected - although no details of it being randomised were released. No severely critical patients, patients with co-morbidities, patients with acute respiratory distress syndrome or severely symptomatic patients were chosen.

Since most COVID-19 deaths in India and the world are a result of the virus and co-morbidities, it is strange that the drug did not test this important group and yet claim they can treat the virus 100 per cent in everyone infected. 

It must also be noted that mild and moderate patients have a higher recovery chance of coronavirus already.

However, Ramdev added that also want to research on “people on ventilators” but the safety of this must be thoroughly investigated first.

Criteria for selection:

  • RT-PCR confirmed cases
  • Patients aged 15-60

Out of the treatment and placebo group, the one that got the drug showed a weaker Interleukin 6 (IL-6) which acts as a pro-inflammatory cytokine. This means that the group with the Ayurvedic drug would have a lesser risk of a cytokine storm.

This is a common occurrence with coronavirus when the immune response goes into overdrive by an excessive and exorbitant amount of cytokine production.

Cytokines are proteins released by a broad range of cells in the body to trigger an immune response against an antigen. When there is an excess, the ‘localised’ inflammation turns into hyper-inflammation, impacting not just the infected areas, but the rest of the body as well. This unregulated and uncontrolled production of cytokines is known as a ‘cytokine storm’ - as the name suggests.

Patanjali claims that taking their drug has caused patients to test negative for the virus and so the “cure is through Ayurveda.”

However, no medicine has a 100 percent recovery rate on all patients - all medicines can cause some complications and side effects in some patients. Think of the warning labels on some of your go-to medicines - they say to be careful if you have certain health conditions, are below or above a certain age, are pregnant etc.

Until data from the trials is not released, and peer-review data is not sought, it is difficult to independently verify claims. They will be releasing all evidence and research in the next 4-5 days.

Patanjali Launches ‘Corona Medicine Kit’

Acharya Balkrishna, MD of Patanjali Ayurved, said that the medicine is made with natural drugs and herbs like any other Ayurvedic medicine. They are planning to launch an app for e-commerce to facilitate the easy home delivery of the medicine.

According to Patanjali, they are planning on selling the tablet in their stores in a week. This, without the release of all research, and without the backing of research bodies like ICMR or the Ayush Ministry - or any other scientific body or journal.

It must be noted that any medicine, especially ones for coronavirus, must be taken after consulting a medical expert. 

They are also launching a corona medicine kit as a preventative for the medicine - but any prophylactic must be taken only after more studies have been done on their safety and after a doctor’s recommendation. The kit is available for Rs 545, however, not many details were revealed about the regulation and safety of this drug.

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

Read Latest News and Breaking News at The Quint, browse for more from fit

Topics:  Quint Fit 

Speaking truth to power requires allies like you.
Become a Member
3 months
12 months
12 months
Check Member Benefits
Read More
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
More News